drugset / Trial / NCT05729074

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

NCT05729074

Phase 1 Unknown 80 enrolled HK inno.N Corporation
RandomizedSequentialTriple-blindTreatment

Summary

This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients

Timeline

Start
2023-02-13
Primary completion
2023-02-25
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IN-A002 Unknown 0.3 % Topical
Subject IN-A002 Unknown 0.5 % Topical
Subject IN-A002 Unknown 1 % Topical
Subject IN-A002 Unknown 3 % Topical
Subject IN-A002 Unknown 5 % Topical
Comparator Pimecrolimus Small molecule 1 % Topical

Indications